ストックスクリーナーアプリを入手
26.80
0.09%
0.025
アフターアワーズ：
26.80
前日終値:
$26.77
開ける：
$26.88
24時間の取引高:
81,978
Relative Volume:
0.32
時価総額：
$1.74B
収益：
-
当期純損益:
$-143.59M
株価収益率:
-9.4914
EPS:
-2.8236
ネットキャッシュフロー:
$-119.47M
1週間 パフォーマンス:
-3.00%
1か月 パフォーマンス:
+0.98%
6か月 パフォーマンス:
+21.93%
1年 パフォーマンス:
+73.46%
1日の値動き範囲:
$26.61
$27.43
1週間の範囲:
$26.11
$28.61
52週間の値動き範囲:
$11.51
$29.80
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
26.80 | 1.74B | 0 | -143.59M | -119.47M | -2.8236 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-15 | 開始されました | H.C. Wainwright | Buy |
| 2025-10-09 | アップグレード | BofA Securities | Underperform → Neutral |
| 2025-06-11 | 開始されました | Guggenheim | Buy |
| 2025-04-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-09-25 | 開始されました | Wedbush | Outperform |
| 2023-08-15 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-05 | 開始されました | Bryan Garnier | Buy |
| 2022-09-13 | 再開されました | JMP Securities | Mkt Outperform |
| 2022-08-23 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-22 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-05-25 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-03-02 | 開始されました | BofA Securities | Neutral |
| 2021-03-02 | 開始されました | Morgan Stanley | Overweight |
| 2021-03-02 | 開始されました | Oppenheimer | Outperform |
| 2021-03-02 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Pharvaris Nv (PHVS) 最新ニュース
Portfolio Recap: Does Pharvaris NV stock have upside surprise potentialQuarterly Portfolio Summary & Scalable Portfolio Growth Methods - baoquankhu1.vn
Movement Recap: How correlated is Pharvaris NV to the S P500July 2025 WrapUp & Weekly Market Pulse Updates - baoquankhu1.vn
Pharvaris N.V. (PHVS) Stock Analysis: Exploring a Promising 65.84% Potential Upside in Biotech - DirectorsTalk Interviews
Responsive Playbooks and the PHVS Inflection - Stock Traders Daily
PHVS: Oral HAE therapy shows strong phase III results, with NDA filing and key data expected this year - TradingView
Should You Buy Pharvaris NV (PHVS) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
PHVS Stock Price and Chart — NASDAQ:PHVS - TradingView
Pharvaris N.V. (PHVS) Stock Analysis: A 65% Upside Potential In The Biotech Sector - DirectorsTalk Interviews
A Look At Pharvaris (PHVS) Valuation As Deucrictibant Advances With New Phase 3 And Phase 2 Data - Sahm
Bain Capital Life Sciences shows 4.3% Pharvaris (PHVS) ownership in Schedule 13G/A - Stock Titan
Understanding the Setup: (PHVS) and Scalable Risk - Stock Traders Daily
Aug Shorts: What is the Moat Score of Pharvaris N.V.2025 Buyback Activity & Smart Swing Trading Techniques - mfd.ru
Pharvaris N.V. (PHVS) Stock Analysis: Potential Upside Of 75% In The Biotech Sector - DirectorsTalk Interviews
Does Pharvaris N.V. stock have upside surprise potentialIPO Watch & Daily Profit Maximizing Trade Tips - mfd.ru
Will Pharvaris N.V. stock gain from lower inflationEarnings Summary Report & Accurate Trade Setup Notifications - mfd.ru
Will Pharvaris N.V. stock recover faster than peersQuarterly Portfolio Review & Comprehensive Market Scan Insights - mfd.ru
Aug Swings: How sensitive is Pharvaris NV to inflationQuarterly Investment Review & Daily Profit Maximizing Tips - baoquankhu1.vn
Oral drug for hereditary angioedema attacks shows Phase 3 data at AAAAI 2026 - Stock Titan
Aug Outlook: Is Pharvaris NV stock a value trapJuly 2025 Big Picture & High Return Trade Guides - baoquankhu1.vn
Aug Gainers: Can Pharvaris NV stock outperform in a bear marketJuly 2025 Sector Moves & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Pharvaris Shares Surge After Strong Phase 3 Results for Oral HAE Treatment - MSN
The Technical Signals Behind (PHVS) That Institutions Follow - Stock Traders Daily
Pharvaris Rings the Opening Bell - Nasdaq
Pharvaris N.V. (PHVS) Stock Analysis: A Biotechnology Gem With 69% Upside Potential - DirectorsTalk Interviews
What’s the fair value of Pharvaris N.V. stockPortfolio Return Summary & Expert Verified Movement Alerts - mfd.ru
Meme Stocks: Is NextNav Inc Equity Warrant exposed to currency risksPortfolio Growth Summary & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Analysts Set Pharvaris N.V. (NASDAQ:PHVS) Target Price at $40.56 - Defense World
Precision Trading with Pharvaris N.v. (PHVS) Risk Zones - Stock Traders Daily
Pharvaris N.V. (PHVS) Stock Analysis: Navigating A 65% Upside In Biotech Innovations - DirectorsTalk Interviews
Pharvaris N.V. (NASDAQ:PHVS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Surprises Report: Can Pharvaris NV stock outperform in a bear marketPrice Action & Expert-Curated Trade Recommendations - baoquankhu1.vn
Layoff Watch: Is Box Inc. a speculative investmentWeekly Market Outlook & Short-Term High Return Ideas - baoquankhu1.vn
Assessing Pharvaris (PHVS) Valuation After Recent Share Price Volatility And DCF Upside Gap - Yahoo Finance
Technical Reactions to PHVS Trends in Macro Strategies - Stock Traders Daily
Pharvaris Sets 2026 Roadmap as Deucrictibant Advances Toward NDA Filing and Phase 3 Readouts - The Globe and Mail
Pharvaris N.V. (PHVS) Stock Analysis: A Promising 83% Upside Potential Amid Biotech Advancements - DirectorsTalk Interviews
Why Pharvaris N.V. stock attracts high net worth investorsMarket Rally & Reliable Price Breakout Signals - Улправда
Why Pharvaris N.V. stock remains a top recommendationOil Prices & Real-Time Market Sentiment Reports - ulpravda.ru
Will Pharvaris N.V. (9EN) stock split increase liquidity2025 Year in Review & Capital Efficient Trade Techniques - Улправда
Street Watch: Why Pharvaris N.V. stock remains a top recommendationDay Trade & Daily Entry Point Trade Alerts - Улправда
How Pharvaris N.V. (9EN) stock reacts to fiscal policiesJuly 2025 PreEarnings & Low Volatility Stock Suggestions - Улправда
How Pharvaris N.V. stock responds to policy changes2025 Market Outlook & Real-Time Volume Trigger Notifications - Улправда
Pharvaris (NASDAQ:PHVS) Shares Up 9.1%Still a Buy? - MarketBeat
Pharvaris (NASDAQ:PHVS) Shares Down 5.7%What's Next? - MarketBeat
What analysts say about Pharvaris NV stockInstitutional Buying Trends & Use Smart Algorithms to Pick Better Stocks - earlytimes.in
LongTerm Outlook Is Uravi Defence and Technology Limited a BuyandHold StockEarnings Volatility Patterns & Low Cost Stock Ideas - earlytimes.in
CEO Moves: Is Pharvaris NV stock trading near support levelsMarket Performance Report & High Conviction Buy Zone Alerts - moha.gov.vn
Pharvaris (NASDAQ:PHVS) Raised to “Hold” at Wall Street Zen - Defense World
Trading the Move, Not the Narrative: (PHVS) Edition - Stock Traders Daily
Pharvaris (NASDAQ:PHVS) Trading 3.8% Higher – What’s Next? - Defense World
Pharvaris N.V. (PHVS) Stock Analysis: Assessing a 66.61% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Pharvaris Nv (PHVS) 財務データ
収益
当期純利益
現金流量
EPS
0.11%
6.00%
大文字化:
|
ボリューム (24 時間):